Context: TAC3/TACR3 mutations have been reported in normosmic congenital hypogonadotropic hypogonadism (nCHH) (OMIM #146110). In the absence of animal models, studies of human neuroendocrine phenotypes associated with neurokinin B and NK3R receptor dysfunction can help to decipher the pathophysiology of this signaling pathway.
Introduction
In the last two years, loss-of-function mutations in TAC3 (MIM 162330) and TACR3 (MIM 162332), the genes encoding neurokinin B (NKB) and its receptor NK3R, respectively, have been described in patients with non syndromic normosmic congenital hypogonadotropic hypogonadism (nCHH) (OMIM #146110), pointing to a fundamental role of this pathway in the physiology of the human gonadotrope axis [1] [2] [3] [4] [5] . The precise mechanisms by which these mutations cause gonadotropin deficiency and CHH are not yet clear [6] , although we recently noted GnRH deficiency in such nCHH patients [3] . In rodents [7] , sheep [8, 9] , goat [10] and non human primates [11] , NKB is expressed throughout the brain [12] and particularly by the same neurons that express kisspeptin and dynorphin. In rats, these neurons form a bilateral, interconnected network that projects to NK3R-expressing GnRH terminals in the median eminence [13] . Kisspeptins have a recognized effect on GnRH secretion [14] . In contrast, the neuroendocrine role of NKB is controversial, as agonists may have either inhibitory or excitatory effects, depending on the animal model and gender [11, [15] [16] [17] [18] . In addition, Tacr3 knock-out mice seem to be fertile [19] and the phenotype of the murine Tac2 knock-out (ortholog of human TAC3) has not been yet reported. Detailed neuroendocrine studies of adult nCHH patients with TAC3/TACR3 mutations may help to decipher the role of this signaling pathway in the pathophysiology of the gonadotrope axis.
The aims of the present work were 1) to evaluate the prevalence of variants in the TAC3 and TACR3 genes in our cohort of nCHH patients; 2) to characterize newly identified mutants responsible for nCHH, at the molecular and functional levels and 3) to examine the neuroendocrine profile of patients with biallelic TAC3/TACR3 mutations to evaluate the hypothesis that NKB and its receptor participate in controlling the frequency of GnRH secretory pulses.
Patients
From a cohort of 352 patients with CHH we selected 173 patients with normosmic nCHH and screened for TAC3 and TACR3 mutations. Gonadotropin deficiency in this setting is characterized by: 1) absent or incomplete puberty at age 18 years; 2) low plasma testosterone levels in men and low to low-normal estradiol levels in women plus low or normal serum gonadotropin levels; 3) otherwise normal pituitary function; 4) normal serum ferritin concentrations; 5) normal magnetic resonance imaging (MRI) of the hypothalamicpituitary region; and 6) a normal sense of smell on olfactometry, and no anosmia/hyposmia in relatives [20] .
Neuroendocrine profiling of TAC3/TACR3-mutated nCHH patients
Since Topaloglu et al. first reported that TAC3/TACR3 mutations can cause nCHH, studies of published pedigrees have shown that the transmission of this genetic form is autosomal recessive [1] [2] [3] [4] . Thus, to study the pulsatility of gonadotropin and free alpha subunit secretion in nCHH patients harboring TAC3/ TACR3 mutations, we enrolled only patients with biallelic mutations, comprising 2 men partially described elsewhere [3] and a new female patient (see Case Reports). Free alpha subunit secretion was evaluated because it has been proposed as the best surrogate for GnRH secretion in nCHH patients with an apulsatile LH profile [21] [22] [23] .
On the same way, for FSH/LH ratio studies, we included 11 patients with biallelic TAC3/TACR3 mutations, of whom 6 are partially described elsewhere [3] and 5 are novel (see Case Reports). The FSH/LH ratios in these 11 patients were compared, using the same assays (see below), with those in patients with CHH of different genetic origins, namely 4 patients with biallelic mutations in KISS1R, 11 with biallelic mutations in GNRHR, 32 nCHH patients with no identified mutations in genes known to cause nCHH and also with those of 50 patients with Kallmann syndrome and mutations in KAL1 (n = 19) or FGFR1 (n = 17), or PROK2/PROKR2 (n = 14) (Information S1).
Results

Case reports
In family 1, three sisters were affected. The proband (subject II-6, Fig. 1A ) was a young woman from a consanguineous family originating from Reunion Island. She was referred at age 24 years because pubertal development and menses had not occurred. She had typical signs of complete hypogonadism, with no breast development but the presence of pubic hair (P4). Her height was 164 cm, her weight 58 kg, and her bone age 14 years. Pelvic sonography showed a small uterus (34 mm high, 28 mm wide, 22 mm thick) and two small ovaries (right, 0.84 mL; left, 1.48 mL), with a few follicles less than 4 mm in diameter. Her karyotype was normal (46, XX). Combined estrogen-progestin replacement therapy induced breast development, an increase in uterus length, and regular menses. Hormonal evaluation after the end of this therapy showed that she still had very low estradiol and LH levels, an undetectable serum inhibin B level, but normal FSH levels as well as a nonpulsatile LH secretion, and an unchanged ovarian aspect on sonography. Pulsatile GnRH administration (90 ng/kg/pulse, every 90 minutes, subcutaneously) was started because she wished to conceive, resulting in increased circulating levels of LH, estradiol and inhibin B, appropriate endometrial thickening, and recruitment of a single dominant follicle of 20 mm. Eleven days later, while still receiving pulsatile GnRH therapy, her progesterone concentration rose to a luteal-phase level (19 ng/mL) and ultrasonography showed the typical aspect of a corpus luteum. This patient's older affected sister (subject II-5, Fig. 1A ), who was evaluated at age 21 years, also had complete hypogonadism and a normal sense of smell. At diagnosis, she had no breast development and sparse pubic hair. Menarche had not occurred. The proband's younger affected sister (subject II-8, Fig. 1A ) was 19 years old when first seen for primary amenorrhea and absent breast development. She was born at term with a normal birth weight after an uncomplicated pregnancy, and grew and developed normally until her early to mid-teen years. On examination, her height was 168 cm and her BMI 23 kg/m 2 . She was at Tanner breast stage 1, pubic hair stage 3, and axillary hair stage 2. Her bone age was 13.5 years at diagnosis.
At diagnosis, the 3 sisters had very low plasma estradiol levels (7.0, 10.7 and 8.6 pg/mL respectively; normal range in the early follicular phase: 22-90 pg/mL) and very low serum LH levels (0.05, 0.1, and 0.16 IU respectively; normal range 2.8-7.1 IU/L), while their FSH levels were normal for the early follicular phase (3.7, 4.3, and 4.6 IU/L respectively; normal range: 2.4-7.0 IU/L). Serum inhibin B levels were undetectable (,10 pg/mL) in the propositus and her older affected sister at diagnosis.
The family 2 proband (subject II-1, Fig. 1B ) was a Caucasian French man born to non consanguineous eugonadal French parents. He was referred at age 19 years-old for absent pubertal development. Physical examination showed typical signs of hypogonadism, with small testes (mean volume: 0.8 mL, normal range in men: 15-30 mL). His height was 180 cm and his weight 68 kg. His karyotype was normal (46, XY). His medical history indicated that he was first referred to a pediatric endocrinologist at age 8 years for micropenis (2.5 cm) and bilateral cryptorchidism, for which he was operated on at age 19 years. At diagnosis he had very low levels of plasma testosterone (0.2 ng/mL; normal range: 2.8-9.0 ng/mL) and serum LH (0.2 IU/L), but his serum FSH (5.4 IU/L) was normal for age and responded (peak: 8.0 IU/L) to GnRH challenge (100 mg intravenously). He was recently reevaluated in September 2010 at 46 years old after a four months interruption of androgen therapy: mean testicular volume was at 1 mL, serum testosterone (0.3 ng/mL) and serum inhibin B (12 pg/mL) were very low; serum LH was low (0.3 IU/L) and FSH was in the normal range (4.4 IU/L).
The family 3 proband (subject II-1, Fig. 1C ) was a Caucasian French man born to non consanguineous eugonadal French parents. He was referred at age 18 years for absent pubertal development. Physical examination showed typical signs of hypogonadism, with small intrascrotal testes (2 mL). His height was 183 cm and his weight 65 kg. His karyotype was normal (46, XY). He had very low levels of plasma testosterone (0.4 ng/mL) and serum LH (0.65 IU/L), but his serum FSH (5.6 IU/L) was normal for age and responded excessively (peak: 11.5 IU/L) to GnRH challenge. Interestingly, his medical history indicated that he was first referred to a pediatric endocrinologist at age 20 months for micropenis (2.3 cm) and right cryptorchidism, for which he was operated on at age 9 years. At age 20 months his levels of testosterone (0.1 ng/mL; normal range: 0.05-0.45) and LH (0.6 IU/L; normal range: 0.1-1.1 IU/L) were in the normal range for chronological age but the FSH was slightly elevated and responded excessively to GnRH challenge (from 2.2 (basal) to 11.2 IU/L (peak); normal range at 20 months: basal, 0.2-1.6 IU/ L; peak, 2.3-5.9 IU/L) [24] .
All the patients studied here had normal MRI of pituitary gland and olfactory bulbs, normal sense of smell on olfactometry and had no renal or craniofacial abnormalities, normal circulating iron, ferritin, and prolactin levels, and normal pituitary, adrenal and thyroid function. None had any other clear neurobehavioral or other phenotypic abnormalities (bimanual synkinesia, dysmorphic facial features, midline anomalies, hearing loss, hypotonia, ataxia, dementia, or polyneuropathy). In particular, all had normal learning ability.
Molecular analysis
The GNRH1, GNRHR, KISS1, KISS1R and FGFR1 exons and intron-exon boundaries were identical to the reference sequences in all the 173 patients studied. Of these 173 patients, 9 propositi (5.2%) carried TAC3/TACR3 variants (1 in TAC3 and 8 in TACR3) ( Table 1 and Fig. S1 ). Two of these mutations, 1 in TAC3 and 1 in TACR3, found in 4 propositi, were previously reported [3] . Here we describe 7 additional different TACR3 variants (5 original and 2 recurrent) in 5 unrelated nCHH propositi (Table 1) . Among them, 3 propositi carried biallelic TACR3 mutations (see case reports), one propositus being homozygous (Fig. 1A) , and two compound heterozygotes ( Fig. 1B and 1C ). In addition, we found 3 monoallelic TACR3 variants in two nCHH propositi (Figs. S3 and S4).
In family 1 propositus, as well as in her affected sisters, we found a homozygous TACR3 deletion (c.483_499del) (subjects II-6, II-5 and II-8, Fig. 1A and Fig. S2 panel A) . The mutation was found in the heterozygous state in the patient's unaffected father (subject I-1, Fig. 1A and Fig. S2 ). The unaffected sister (subject II-1, Fig. 1A ) was a wild-type homozygote (Fig. S2 ). This deletion results in a frameshift from codon 161 and the emergence of a premature stop codon at position 183 (Gln161HisfsX23), truncating NK3R after the third transmembrane segment (Fig. 1A and Fig. S1 ). This deletion was not found by genomic sequencing in 200 chromosomes from eugonadal ethnically matched subjects.
In propositus II.1 from family 2 ( Fig. 1B) we found a compound heterozygous TACR3 mutation (c.824G.A and c.1003C.T). The c.824G.A substitution produces a stop codon in the 5 th transmembrane segment (p.Trp275Stop) of NK3R (Fig. 1B, Fig. S1 and Fig. S2, panel B) . This recurrent mutation has previously been reported in the homozygous and monoallelic states by Gianetti et al. [4] . It was found in the heterozygous state in the unaffected father. The c.1003C.T substitution which produces a stop codon in the junction between the third extracellular loop and the seventh transmembrane domain (p.Gln335Stop) of NK3R (Fig. 1B, Fig. S1 ) was found in the heterozygous state in the unaffected mother. These 2 mutations were not found by genomic sequencing in 200 chromosomes from ethnically matched eugonadal control subjects.
In propositus II.1 from family 3 ( 
Modeling and functional studies of the missense mutations
The Tyr267 residue is highly conserved among the three human tachykinin receptors and in all NK3R orthologs ( Fig. 2A) . Modeling was used to predict the potential impact of this point mutation on the three-dimensional organization of NK3R. We found that the hydrophobic Tyr267 residue is located in the middle of the fifth transmembrane segment and points towards the lipid bilayer (Fig. 2B) . Introduction of an asparagine residue at position 267 (Y267N mutation) places a polar residue in a highly hydrophobic environment. Thus, it is likely that the asparagine side chain, in order to adopt a buried position, will induce transmembrane reorganization (twist or rotation). Therefore, the Tyr267Asn mutation leads probably to NK3R misfolding and dysfunction.
To test this misfolding hypothesis, we performed immunocytochemical studies in both permeabilized and non permeabilized cells in order to evaluate the subcellular localization of the Tyr267Asn mutant. In non permeabilized cells the wild-type NK3R molecule was located at the membrane (Fig. 2C, upper  panel) . In contrast, the Tyr267Asn mutant was not detected at the membrane, suggesting defective trafficking [25] . To ascertain that the mutant was efficiently expressed, we performed immunocytochemical experiments in permeabilized cells. In this condition, both wild-type and mutant proteins were detected. Compared to wild-type, the NK3R mutant was localized in the perinuclear region suggesting a misfolding (Fig. 2C, lower panel) . Thus, the substitution of Tyr267 by asparagine impaired the proper targeting of the receptor to the cell surface.
To quantify and compare the stimulation effect of neurokinin B on wild-type and mutant NK3R, we performed dose-response curves for SRE luciferase assay in HEK 293T cells. Consistent with immunocytochemical and modeling studies, functional analyses clearly showed that mutated NK3R failed to stimulate a p44/42 MAP-sensitive SRE reporter gene contrary to the wildtype receptor which showed a clear dose-response stimulation in the presence of neurokinin B (Fig. 2D) .
Similar modeling and functional studies were performed to characterize separately the 3 other variants (Lys286Arg, Met306Ile and Arg230His). In addition, the two Lys286Arg and Met306Ile mutations located on the same chromosome were assessed as double mutant. These analyses, detailed in supporting information (Fig. S3 and Fig. S4 ), suggest that in fact these variants did not affect the structure and the function of NK3R. Therefore they can not be considered as causative of the disease. For that reason, clinical features of these propositi were not detailed here.
Analysis of free alpha subunit (FAS) and gonadotropin pulsatility in nCHH patients with biallelic TAC3 or TACR3 mutations Serum FAS pulsatility was analyzed in subject II.6 from family 1 (Fig. 1A and Table 2 ), who harbored a homozygous mutation in TACR3, and in two subjects partially described elsewhere [3] with either a homozygous TAC3 or a homozygous TACR3 mutation. Endogenous serum FAS levels are shown for two of these subjects in Fig. 3A and 3B .
Mean (6SD) basal FAS concentrations in these 3 patients were low (0.1960.05 IU/L), with a low mean pulse frequency (1.261.3 pulses every four hours (mean6SD); normal range: 2.3-3.0) and a low amplitude of detected pulses (0.260.1 IU/L). As expected, pulsatile GnRH administration to these 3 nCHH patients significantly (p,0.01) increased mean FAS levels (1.160.19 IU/ L) and the FAS pulse frequency (3.360.6 pulses every four hours) and amplitude (0.4160.11 IU/L, P,0.05), in line with GnRH dependency of pituitary FAS secretion [23] .
Analysis of basal LH and FSH secretion overnight at 10-min intervals for 4 h in subject II.6 from family 1 (Fig. 1A and Table 2) showed very low levels and a nonpulsatile pattern of LH secretion, whereas mean baseline FSH levels were significantly higher (Fig. 3C) . On day 13 of pulsatile GnRH administration (90 ng/ kg/pulse, every 90 min, sc), pulses of LH were detected, synchronously with the GnRH boluses (Fig. 3D ) and concomitantly with an increase in serum estradiol and inhibin B levels and a slight serum FSH decrease. 
Serum FSH/serum LH ratio in patients with TAC3/TACR3 mutations
The FSH/LH ratios in 11 subjects with biallelic TAC3/TACR3 mutations ( Table 2) (Fig. 4B ).
Discussion
We found here TAC3/TACR3 mutations in 5.2% of our nCHH population, a prevalence similar to that described by Gianetti et al [4] in a population of Caucasians, Asians and African-Americans. In this series, all the subjects with nCHH and biallelic TAC3/ TACR3 mutations were born to healthy heterozygous parents. This reinforces the autosomal recessive transmission of these two genetic forms of nCHH, as reported by Topaloglu et al. and us [1] [2] [3] .
In the first family, we identified a new homozygous mutation in TACR3 that leads to a frameshift and truncation of the receptor after the third transmembrane domain and therefore almost certainly has a deleterious effect. In two french families of Caucasian origin we found three TACR3 mutations with compound heterozygous status. They share the same mutation, which generates a stop codon (Trp275stop) and leads to truncation of the protein after the fifth transmembrane domain, indicating that it is also certainly deleterious. This recurrent mutation has been found in the homozygous state in Caucasian American patients with nCHH [4] , suggesting either a founder effect in this population or a mutation hotspot in this genomic region. The propositus of the second family also carried on the other allele a novel non sens mutation (Gln335stop) which leads to truncation of the protein after the third extra cellular loop also indicating that it is certainly deleterious. The propositus of the third family also carried a new missense mutation, Tyr267Asn, on the other allele, as revealed by studies of the parents. This mutation, affecting a conserved amino acid in the fifth transmembrane domain, affects the conformation of this domain, as shown by molecular modeling. The deleterious nature of this variant was confirmed by functional analyses showing altered MAP kinase-mediated NK3R signaling. This dysfunction is likely due to receptor misfolding and to defective plasma membrane targeting, as shown by immunocytochemical studies. Such a mechanism has already been reported for mutations affecting another 7-transmembrane-domain receptor (GnRHR) and leading to nCHH [25] .
Analysis of gonadotropin concentrations in patients with biallelic TAC3/TACR3 mutations showed very weak and apulsatile LH secretion, contrasting with preserved FSH concentrations. This profile, already found in other nCHH patients with biallelic TAC3/TACR3 mutations [1, 3] , points to the existence of lowfrequency (and probably low amplitude) endogenous GnRH [3] ). Arrows indicate exogenous GnRH boluses (7 mg). Panel B. FAS concentration in a woman with nCHH caused by a mutation in TACR3 (subject II-6 in family I, Fig. 1A ), before and on day 13 of pulsatile GnRH administration. Arrows indicate exogenous GnRH boluses (5 mg). Asterixes denote detectable FAS pulses, using Thomas' algorithm [24] . See Patients and Methods for details. Panel C. Pattern of gonadotropin secretion in a woman with complete nCHH and TACR3 mutation (subject II-6 in family I, Fig. 1A ). Basal LH concentration was very low and FSH concentration was in the normal range. Panel D. LH pulsatility in this woman was restored by pulsatile GnRH administration, and the serum FSH level fell slightly during pulsatile GnRH administration. Serum estradiol (E2) and inhibin B (IB) levels before and after GnRH administration are indicated respectively at the top of panel C and D. doi:10.1371/journal.pone.0025614.g003 secretion [3] . We actually observed slow FAS secretion in all three patients studied, strongly supporting this hypothesis. Moreover, pulsatile GnRH administration at a physiological frequency reestablished pulsatile LH and FAS secretion, and decreased the FSH/LH ratio. These pattern of response to pulsatile GnRH treatment are different from those reported in hypothalamic CHH patients, where GnRH leads to a rise in FSH, sometimes to supraphysiologic levels [26] , further underlining the originality of the TAC3/TACR3 mutated nCHH patients' neuroendocrine phenotype. All these data strongly suggest that the gonadotrope deficiency in subjects with TAC3/TACR3 mutations is linked to a slowing of the frequency of endogenous GnRH secretion. It is therefore likely that neurokinin B, via its receptor NK3R, acts on the hypothalamus to regulate, either directly or indirectly (via kisspeptin/dynorphin/NKB neurons) [10, 13] , the frequency of GnRH release into the hypothalamo-pituitary portal system. Our hypothesis is in line with a model recently proposed [10, 16] whereby kisspeptin, Dyn, and NKB act autosynaptically on kisspeptin neurons in the Arc to shape the pulsatile secretion of kisspeptin and hence GnRH release.
The molecular mechanisms by which low pattern of pulsatile GnRH secretion into portal blood favors FSH secretion by gonadotrope cells remain to be established. In contrast to the LHb subunit gene, it has been shown in vitro that FSHb subunit transcription is preferentially stimulated at low rather than high frequencies of pulsatile GnRH [27] . Because the synthesis of FSHb is the rate-limiting step in FSH production, how FSHb transcription is regulated is key to understanding the control of FSH release. In the context of the rFSHb promoter, Ciconne et al. had recently established that GnRH stimulates transcription by increasing bound histone modifying enzyme CBP [28] . This increase in CBP is mediated in turn through the transcription factor CREB, bound to the FSH b CRE site. These authors also showed that mutation of this CRE site abolishes preferential FSH b transcription at low GnRH pulse frequency, implicating this site as an important mediator of GnRH pulse frequency-dependent FSH b gene expression [28] .
The existence of a high FSH/LH ratio prior to any treatment in a significant number of patients with biallelic TAC3/TACR3 mutations, contrary to patients with other genetic causes of CHH, suggests that this ratio could serve as a diagnostic marker to prescreen for TAC3/TACR3 mutations in untreated patients with nCHH. This would narrow down the number of subjects in whom sequencing is necessary and would thus reduce the cost of genetic studies in this setting, although larger studies will be necessary before recommending this diagnostic approach.
All 11 patients with biallelic TAC3/TACR3 mutations that we have analyzed to date had nCHH persisting into adulthood (from 18 yrs-old to 46 yrs-old). These results, in keeping with data reported by Topaloglu et al. [1] , Guran et al. [2] and Fukami et al. [5] , indicate that NKB and its receptor NK3R are crucial for physiological GnRH secretion after puberty, and not only during fetal life as suggested by Gianetti et al. [4] . Furthermore only one documented case of reversible nCHH in patients with TAC3 biallelic mutations have been reported to date [4] , indicating that this phenomenon does not predominate in this genetic form of CHH.
In conclusion, TAC3/TACR3 mutations are an important genetic cause of nCHH that should be particularly searched in patients with a high serum FSH/LH ratio. Patients with nCHH and biallelic TAC3/TACR3 mutations represent a useful model for deciphering the physiological role of NKB and its receptor NK3R in the gonadotrope axis. Such human models are all the more important as there is currently no genetic murine model with which to explore the precise consequences of this signaling dysfunction for hypothalamic GnRH secretion.
Methods
All the participants gave their written informed consent for hormonal exploration and genetic analyses, in keeping with the provisions of the French Bioethics Law and the Declaration of Helsinki and after approval by the Bicêtre Hospital ethic committee (Comité de protection des personnes Ile de France, Hôpital Bicêtre).
Hormone assays
We measured serum levels of LH, FSH, inhibin B, testosterone and estradiol levels with immunoradiometric assay, enzyme-linked immunosorbent assay, or radioimmunoassay, respectively, as previously reported [29, 30] . The detection limits of the LH and FSH assays were respectively 0.15 IU/L and 0.2 IU/L. The intraand interassay coefficients of variation were, respectively, 1.5 and 5.2% for LH, 2.7 and 5.5% for FSH. Endogenous luteinizing hormone and alpha-subunit secretion, analyzed with Thomas' algorithm, was evaluated overnight at 10-minutes intervals, as reported elsewhere [29, 30, 31] . Serum free alpha-subunit (FAS) levels were measured as previously reported [32] , using an immunoradiometric assay (IRMA) with two monoclonal antibodies (Immunotech, Marseille, France). Cross-reactivity of this immunoassay is less than 0.1% for dimeric hormones (including CG, LH, FSH, and TSH) and 0% for the free b-subunits of these hormones. For FSH/LH ratio determination, we used blood samples drawn at diagnosis from untreated CHH patients referred to the Endocrinology and Reproductive Diseases department of Hôpital Bicêtre and sera stored at 280uC. All gonadotropin assays were performed in a single run in order to avoid interassay variations.
DNA analysis
Genomic DNA was extracted from white blood cells by using standard procedures.
TAC3 coding exons 2, 3, 4, 5 and 6 and intron-exon junctions and TACR3 coding exons 1, 2, 3, 4 and 5 and intron-exon junctions were amplified by PCR and sequenced as previously described [1, 3] . Sequence variations were found on both strands and confirmed in a separate PCR.
GNRHR, GNRH1, KISS1R, KISS1, KAL1, FGFR1 and PROK2/ PROR2 were also analyzed as previously described, with minor modifications [29] [30] [31] [33] [34] [35] [36] .
Modeling studies
The model of NK3R was generated by homology, using as template the crystal structure of rhodopsin, a hepta-transmembrane protein, with the Modeller package (version 9.8) [37] . Loops differing in length between NK3R and rhodopsin were reconstructed using the structural proteins bank (rotamer library) included in the O package [38] . NK3R mutants were generated using the same package. Statistics, calculated with Procheck, showed that .98.6% of the residues in the Ramachandran plot are in the most favored or allowed regions and that side-chain stereo parameters are inside the range or better than the statistics derived from a set of crystal structures of at least 2.0 Å resolution. In addition, the PROSAII program gave a combined Z-score (Cb and surface potentials) of 23.34, a value in the range of structured proteins. These results suggest that the protein is of good quality and suitable for analysis.
Directed mutagenesis
NK3R mutants were reproduced by site-directed mutagenesis using the pcDNA3.1+ plasmid encoding human NK3R with an hemagglutinin (HA) tag localized on the extracellular NK3R Nterminal extremity (Missouri S&T cDNA Resource Center) with the QuickChange Stratagen II kit (Stratagene, La Jolla, CA). Clones were verified by sequencing.
Luciferase reporter gene assays
Tachykinin G protein-coupled receptors signal through several second messenger pathways including phosphoinositide and MAP kinase pathways (ERK 1/2) [39] . We thus used the luc2P/SRE/ Hygro plasmid (Promega) which can induce luciferase production in response to MAP kinase activation as a reporter gene system [40] . HEK 293T cells (12,000 cells/well) were seeded 72 h before testing in high-glucose Dulbecco's minimal essential medium (Invitrogen, Cergy Pontoise, France) containing 2 mM glutamine, 100 IU/mL penicillin, 100 mg/mL streptomycin, and 10% heatinactivated fetal calf serum at 37uC in 96-well plates. Twenty-four hours before testing, the cells were cotransfected in serum free OptiMEM, using Lipofectamine 2000 as recommended by the manufacturer (Invitrogen) with the plasmids coding for the wildtype or NK3R mutants, the luc2P/SRE/Hygro plasmid (Promega) and pRSV-beta-galactosidase plasmid. On the test day, neurokinin B was added at seven dilutions (from 10 210 to 10 26 M) to the culture medium. After incubation for 5-6 h the cells were harvested and assayed for b-galactosidase and luciferase activities as previously described [41] , using a luminometer (Victor, Perkin Elmer). To standardize the transfection efficiency, the relative light units obtained in the luciferase assay were divided by the optical density obtained in the b-galactosidase assay. Maximum activity was considered at 5x10 27 M NKB. Prism version 3.02 (GraphPad Software Inc., SanDiego, CA) was used for curve fitting from at least three independent experiments performed in triplicate. Results are expressed as mean6SEM.
Immunocytochemistry COS-7 cells were grown in 24-well plates containing glass coverslips (14-mm diameter). After transfection with the expression vector coding for HA-NK3R, cells were processed as previously described [42] . Briefly, cells were fixed with 4% paraformaldehyde and permeabilized for 10 min with a 0.2% solution of Triton X100 diluted in PBS. Cells were then incubated overnight at 4uC with an anti-HA antibody (clone 3F10, Roche Applied Science), followed by an anti-rat fluorochrome-coupled secondary antibody (Dylight 549, Jackson ImmunoResearch Laboratories) for 30 min. Nuclear counterstaining was performed with 0.5 mg/mL DAPI (49,69-diamidino-2-phenylindole). Fluorescent cells were observed with an Olympus Provis AX70. Images were acquired with Qcapture Pro version 5.1 (Q Imaging Inc.). For live cell staining, cells were incubated for 1 h with the anti-HA antibody before fixation with 2% paraformaldehyde and direct incubation with the Dylight 549 secondary antibody. After extensive washing with TBS-Tween (0.1%), cells were post-fixed with 2% paraformaldehyde and counterstained with DAPI, rinsed quickly in water, and then mounted on slides with ProLong Gold mounting medium (Molecular Probes). A Zeiss LSM-510 confocal scanning laser microscope (Carl Zeiss, Thornwood, NY) was used to acquire Zseries of focal planes using a Plan Apochromat 63 oil objective. Figure S1 Schematic representation of the human NK3R variants found in a cohort of 173 normosmic CHH. The mutated residues are indicated by red circles (see also Table 1 . S1 ). We tested the activity of the mutant receptor on the SRE luc reporter gene (panel E (upper)) and showed that there was no meaningful difference between the p.Lys286Arg mutant (green squares) and the wild-type NK3R (black circles). The c.918G.A produces a missense mutation (p.Met306Ile) located in the sixth transmembrane segment of NK3R (Fig. S1) . It is poorly conserved in the three human tachykinin receptors and NK3R orthologs (panel C). Using the three-dimensional model, we found that Met306 (M306) is located at the middle of the sixth transmembrane segment and fully surface exposed (panel D). We tested the activity of the p.Met306Ile variant on the SRE-Luc reporter gene system (panel E (middle)) and showed that there was no difference between the p.Met306Ile mutant (green triangles) and the wild-type NK3R (black circles). To verify that the p.Lys286Arg variant did not interfere with the function of the p.Met306Ile mutant we performed a double p.Lys286Arg+p.Met306Ile mutant. The activity of the double mutant on the SRE-Luc reporter gene system (orange triangles) was similar to that in the wildtype NK3R (black circles) (panel E (lower)). (DOC) Figure S4 Molecular characterization, functional consequences and modeling of Arg230His NK3R variant. In propositus II.1 from family 5 (Panels A and B) we found one variant (c.689G.A) at the heterozygous state. This variant, located in the second extracellular loop of NK3R, produces a missense mutation (p.Arg230His)(see also Fig. S1 ). It is partly conserved in the three human tachykinin receptors and almost completely conserved in NK3R orthologs (Panel C). Using the three-dimensional model, we found that Arg230 (R230) is located in the second extracellular loop and solvent-exposed (Panel D). We tested the activity of the mutant receptor on the SRE-Luc system (Panel E) and showed that the Arg230His mutation has no consequence on the receptor activity. (DOC) Information S1 Mutations in patients with other genetic causes of CHH or Kallmann syndrome included for the analysis of serum FSH/LH ratio (Fig. 4A) . (DOC)
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